JPRN-UMIN000011474已完成2 期
Activated dendritic cell-based tumor-specific immunotherapy against high grade glioma-Phase II trial - Immunotherapy against high-grade glioma
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Within 28 days afetr the last treatment against cancer 2. Severe systemic infection, hematostatic dysfunction, and organ disorder 3. Steroid treatment except used for cerebral decompression 4. Hypersensitivity to DC vaccine 5. Severe immunological disorders (autoimmune disease, immunosuppression) 6. Multiple cancers 7. Anaphylaxis to synthetic peptides
研究者
相似试验
已完成
1 期
Dendritic cell-based tumor-specific immunotherapy against malignant brain tumor - Phase I clinical trialMalignant brain tumor (malignant glioma)JPRN-UMIN000000914Shizuoka Cancer Center12
已完成
2 期
Dendritic cell-based immunotherapy against metastatic melanoma patientsmetastatic melanomaJPRN-UMIN000006849Shizuoka Cancer Center24
已完成
2 期
Dendritic Cell Vaccine for the treatment of Stage IIIb Cervical Cancer patientsCTRI/2016/12/007530Department of Science and Technology DST54
已完成
不适用
Dendritic cell-based immunotherapy for ovrian cancer patients.NeoplasmsKCT0000831Asan Medical Center10
尚未招募
不适用
Dendritic cell-based immunotherapy combined with low-dose cyclophosphamide in patients with malignant pleural mesotheliomamesothelioma10035597NL-OMON32554Erasmus MC, Universitair Medisch Centrum Rotterdam10